TrialFind
SearchAbout
Saved trials

Filters

Sort by

Recruitment

Status

Phase

Age group

TrialFind

Making clinical research accessible to everyone. Search 500,000+ trials in plain English.

NavigationHomeSearch TrialsAboutSaved Trials
Data & LegalClinicalTrials.govPrivacyRegulatory infoContact

© 2025 TrialFind. Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

CompletedPhase 1 / Phase 2

Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease

This combined phase 1/2a clinical trial is to investigate the safety, dose limiting toxicity (DLT), and exploratory efficacy of three repeated intraventricular administrations of NEUROSTEM® (human umbilical cord blood-derived mesenchymal st

Seoul, South Korea
View details
Load more trials
RecruitingPhase 2

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

To investigate the effect of trazodone on sleep, hippocampal-dependent memory and hippocampal excitability. The investigators hypothesize that trazodone will improve total sleep time and proportion of time in Slow Wave Sleep (SWS).

Baltimore, Maryland, United States
View details
Completed

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured by the AUC o

Santa Ana, California, United States
View details
CompletedPhase 2

Efficacy and Safety Study of ABT-384 in Subjects With Mild-to-Moderate Alzheimer's Disease

The purpose of this study is to test if the investigational medication, ABT-384, is a safe and effective treatment for adults with mild-to-moderate Alzheimer's Disease.

Kazan', Russia+29 more
View details
Active, not recruitingEARLY_Phase 1

Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderat

Belmont, Massachusetts, United States
View details
CompletedPhase 2

Development of NIC5-15 in the Treatment of Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of NIC5-15in the treatment of Alzheimer's Disease.

The Bronx, New York, United States
View details
CompletedPhase 2

Imaging Tau in Alzheimer's Disease and Normal Aging

This study is being done to learn about tau tangles in Alzheimer's disease. A type of positron emission tomography (PET) scan is used to measure the abnormal accumulation of protein called tau in the brain.

New York, New York, United States
View details
Completed

Validity and Reliability of Turkish Version of Bayer Activities of Daily Living Scale

The aim of our study is to verify the validity and reliability of the Turkish version of B-GYA.

Istanbul, Turkiye, Turkey (Türkiye)
View details
UnknownPhase 1

Encapsulated Cell Biodelivery of Nerve Growth Factor to Alzheimer´s Disease Patients

Cholinergic neurons in the basal forebrain project widely to the cerebral cortex and hippocampus. These neurons depend on nerve growth factor (NGF) from their target areas for survival.

Stockholm, Sweden
View details
Recruiting

Cognitive Neurology Unit Clinical Registry

A Prospective Comparative Study Of Monoclonal Antibodies For The Treatment Of Alzheimer's Disease

Boston, Massachusetts, United States
View details
CompletedN/A

Cognitive Stimulation in Older Adults With Alzheimer's Disease

This multicentre study, employing a randomised controlled repeated measures experimental design, will be conducted in several Portuguese institutions that provide care and support services for older adults diagnosed with mild to moderate Al

Leiria, Leria, Portugal+38 more
View details
CompletedPhase 2

Alzheimer's Disease Acitretin Medication

The trials investigates the changes of cerebral spinal fluid (CSF) soluble alpha-secretase cleaved APP (APPsα) levels under oral therapy with acitretin 30mg daily in patients with mild to moderate Alzheimer's disease (AD).The present study

Mainz, Rhineland-Palatinate, Germany+1 more
View details
CompletedPhase 2

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

The purpose of this study is to find out if insulin, when administered as a "nasal spray" into the nasal passages, improves memory in adults with mild cognitive impairment (MCI) or Alzheimer's disease.

Seattle, Washington, United States
View details
CompletedPhase 2

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in participants with mild to moderate Alzheimer's disease who have participated in and completed the treatment pe

Phoenix, Arizona, United States+85 more
View details
TerminatedPhase 3

Open-label Extension for Phase 3 Clinical Trials of Simufilam

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.

Chandler, Arizona, United States+133 more
View details
CompletedN/A

TACAD Program for Asian American Family Caregivers of Persons Living With Alzheimer's Disease

The purpose of the proposed study is to preliminarily evaluate Technology-based information and coaching/support program that is tailored for Asian American midlife women who are family caregivers of patients living with Alzheimer's disease

Austin, Texas, United States
View details
UnknownN/A

Early-onset and Late-onset Sporadic Alzheimer's Disease (AD)

Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown.

Marseille, France, France
View details
TerminatedPhase 2

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

This was a phase II, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of Semorinemab in participants with prodromal to mild Alzheimer's disease. An optional 96-week open-label extension period was avail

Birmingham, Alabama, United States+132 more
View details
UnknownN/A

Health Behavior Change in Midlife Adults at Risk for Alzheimer's Disease

Modifying health behaviors like physical activity level, diet, stress, and mental activity level can lower risk for Alzheimer's disease, but many middle-aged and older adults find it difficult to sustain health behavior changes over the lon

Providence, Rhode Island, United States
View details
UnknownN/A

Davos Alzheimer's Collaborative Healthcare System Preparedness to Increase Cognitive Assessment Rates for Older Adults

In this study the investigators explore a pragmatic strategy to increase cognitive screening rates in the community. The investigators will compare the monetary value of different combinations of SCD questionnaires, digital cognitive tests,

München, Bavaria, Germany
View details